FindTrial
Sign In

Multicenter Validation Study on the Value of GPC3 in Prognosis Assessment of Hepatocellular Carcinoma and the Efficacy of the GDATA Model in Screening for HCC

Multicenter Validation Study on the Value of GPC3 in Prognosis Assessment of Hepatocellular Carcinoma and the Efficacy of the GDATA Model in Screening for HCC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126259
Enrollment
Unknown
Registered
2026-06-05
Start date
2026-10-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

BCLC Stage 0-A HCC Curative Treatment Cohort:None
Chronic Liver Disease:None

Sponsors

Fuyang Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically or clinically confirmed HCC; 2. BCLC stage 0-A; 3. Received curative treatment (surgical resection, liver transplantation, or local ablation);

Exclusion criteria

Exclusion criteria: 1. Received prior treatment for liver cancer before radical therapy; 2. Concurrent other malignancies; 3. Incomplete baseline data.

Design outcomes

Primary

MeasureTime frame
Recurrence-Free Survival (RFS);C-index;—

Secondary

MeasureTime frame
Calibration;—

Countries

China

Contacts

Public ContactJing Xu

Fuyang Second People's Hospital

fyey2563945@163.com+86 558 256 3945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026